ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Survival outcomes of patients with advanced ovarian cancer receiving more than three cycles of neoadjuvant chemotherapy followed by interval cytoreductive surgery.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The objective of this study was to describe survival outcomes in patients with advanced ovarian cancer according to the number of neoadjuvant chemotherapy (NACT) cycles received and to explore their relation to cytoreduction and pathological response. Materials and methods: The study included 70 patients with advanced ovarian cancers presented to our center receiving neoadjuvant chemotherapy followed by interval debulking surgery and continuation of adjuvant treatment. Files of these patients were reviewed and data were extracted. Patients' outcomes were determined in terms of progression free survival (PFS) and overall survival (OS). Results: The median age was 59 years. Median PFS and OS was 33 months. Univariate PFS and OS analysis revealed that optimal cytoreduction and achieving pathological complete response (PCR) significantly reduced the hazard of progression and death. However, the time interval between the end of NACT and surgical debulking and the number of adjuvant chemotherapy cycles received didn't affect the PFS or OS significantly. In multivariate analysis of PFS and OS, it was found that achieving PCR significantly affect the survival outcomes and is considered as independent prognostic and predictive factor for PFS and OS. The rate of optimal cytoreduction was significantly correlated with the number of NACTx cycles received. Conclusions: Our study suggests that increased number of neoadjuvant chemotherapy cycles in patients with advanced ovarian cancer don't adversely affect the survival outcomes and that the rate of optimal cytoreduction and achieving PCR significantly affect patients' survival outcomes. Rate of optimal cytoreduction significantly increased with the increased number of neoadjuvant chemotherapy received. Keywords: Ovarian cancer, neoadjuvant chemotherapy, interval debulking, optimal debulking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.